New cancer clinical trial: A Phase 1 Study of HLX10, a Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein in Patients With Advanced Solid Tumors
Published on: March 19, 2018 at 12:00PM Condition: Solid Tumor Intervention: Drug: HLX10 Sponsor: Henlix, Inc Recruiting
http://ift.tt/2u63jxY
No comments:
Post a Comment